Pharmaniaga Returns to the Black After Two Quarters of Losses
Pharmaniaga Bhd returned to the black after two consecutive quarters of losses, thanks to higher revenue and cost control measures that lowered expenses.
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript Summary
The following is a summary of the Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript:Financial Performance:Astellas Pharma reported a revenue decrease of 2% YoY due to Lexiscan generics' im
Pharmaniaga Says It Is Confident of Financial Recovery After Auditors Again Flag Going-concern Issues
KUALA LUMPUR (May 10): Pharmaniaga Bhd (KL:PHARMA), whose weak financials have just been flagged by its independent auditor for a second consecutive year, assures shareholders that it is committed to financial recovery and has made “strong and steady progress” on it.
Pharmaniaga COO Mohamed Iqbal Abdul Rahman Retires After 13 Years
Mohamed Iqbal Abdul Rahman has retired as Pharmaniaga Berhad chief operating officer (COO) effective immediately, ending his 13-year tenure with the company.
Pharmaniaga Trims Loss in Q4 2024
Pharmaniaga (KLSE:PHARMA) incurred a loss attributable to owners of 32.7 million ringgit in the fourth quarter ended Dec. 31, 2023, much lower than 644.4 million ringgit a year earlier. Loss per share
Pharmaniaga in the red for second straight year, records 4Q loss on lower revenue
Pharmaniaga Bhd logged a net loss of RM32.72 million for the final quarter of 2023, as revenue fell on lower sales from its concession business.
Pharmaniaga, Malaysia's Health Ministry Sign Seven-Year Consession Deal
Pharmaniaga (KLSE:PHARMA) said its unit Pharmaniaga Logistics signed a concession deal with the Ministry of Health of Malaysia to supply and deliver medical products to offices and facilities operated
Pharmaniaga Shares Surge on Seven-year Medical Supply Logistics Deal With MOH
KUALA LUMPUR (Jan 4): Pharmaniaga Bhd's stock price surged as much as 13.2% to 43 sen on Thursday, following the pharmaceutical company's signing of a seven-year concession agreement with the Ministry of Health (MOH) for medical supply logistics services.
Tonghua Dongbao Pharma Unit Enrolls First Subject for Clinical Trial of Diabetes Drug
Tonghua Dongbao Pharmaceutical's (SHA:600867) unit, Dongbao Purple Star (Hangzhou) Biopharmaceutical, enrolled the first subject for the phase I clinical trial for the THDBH110 capsules. The Chinese p
Pharma Stocks With Nice Dividends: The RX Investors Need -- Barrons.com
By Lawrence C. Strauss Many healthcare stocks have been under the weather this year amid concerns about the advent of weight-loss drugs, weaker Covid-related sales, and the market's narrow focus on a
Can Wegovy Fight Alcoholism? For Big Pharma, This Isn't a Priority
Syphilis Testing Market Size to Grow by USD 2.22 Billion From 2023-2028 | Abbott Laboratories, AdvaCare Pharma, Beckman Coulter Inc. and More Among the Key Companies in the Market - Technavio
The syphilis testing market size is expected to grow by USD 2.22 billion, accelerating at a CAGR of over 6.7% during the forecast period, according...
BridgeBio Pharma(BBIO.US) Director Sells US$73,500 in Common Stocks
$BridgeBio Pharma(BBIO.US)$ Director Scott Randal W. sold 2,500 shares of Common Stocks on Dec 1, 2023 at an average price of $29.4 for a total value of $73,500.Source: Announcement What is statement
Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will It Be a Boost For Pharma Stocks Too?
In September, Biden unveiled a $240 million investment to combat cancer, augmenting the administration's "Cancer Moonshot", an initiative with an array of new health resources. The funding, allocated
Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And Royalties
Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And Royalties
Aclaris Therapeutics Announces Patent License Agreement With Sun Pharma for Alopecia
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an
Ocuphire Pharma, Inc. (OCUP) Ocuphire Pharma Corporate Update Call (Transcript)
Ocuphire Pharma, Inc. (OCUP) Ocuphire Pharma Corporate Update Call (Transcript)
Analyst Expectations for Marinus Pharma's Future
Over the past 3 months, 5 analysts have published their opinion on Marinus Pharma (NASDAQ:MRNS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a
MaaT Pharma : Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers)LYON, France--(BUSINESS WIRE)--$MAAT--Regulatory News:MaaT Pharma (EURONEXT: MAAT
Horus Pharma Is Strengthening Its International Expansion in Support of Its Growth
- Signature of 8 new distribution agreements - With 5 subsidiaries in Western Europe and 19 collaborations, Horus Pharma is making its high-quality ophthalmological products available in more than 30
No Data